Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-23T14:46:09.805Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting

Published online by Cambridge University Press:  26 July 2018

Kanupriya Chaturvedi ,
Joni S. Steinberg  and
Christopher S. Snyder
Kanupriya Chaturvedi
Affiliation:
The Congenital Heart Collaborative, Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
Joni S. Steinberg
Affiliation:
Department of Global Health Management & Policy, Tulane University of Public Health and Tropical Medicine, New Orleans, LA, USA
Christopher S. Snyder*
Affiliation:
The Congenital Heart Collaborative, Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
*
Author for correspondence: C. S. Snyder, MD, Division Chief, Department of Pediatric Cardiology, Rainbow Babies and Children’s Hospital, Case Western Reserve University, MS RBC 6011, 11100, Euclid Avenue, Cleveland, OH 44106, USA. Tel: 216 844 8529; Fax: 216 844 5478; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Infantile haemangioma is one of the most commonly known benign vascular tumours of infancy and childhood, having an incidence of 3–10%. Most lesions regress spontaneously; however, some may require treatment owing to their clinical and cosmetic effects. Propranolol has become the treatment of choice for infantile haemangioma, but treatment protocols are largely institutional based without any specific consensus guidelines. Our aim was to evaluate the cost-effectiveness of propranolol use as inpatient versus outpatient therapy.

Methods

A decision tree model was created depicting alternate strategies for initiating propranolol treatment on an inpatient versus outpatient basis combined with the option of a pretreatment echocardiogram applied to both strategies. Cost analysis was assumed to be based on treatment of haemangioma in patients who were born at term, had no chronic illnesses, a non-life-threatening location of the haemangioma, and those who were not taking any other medications that could potentiate the side effects of propranolol. A sensitivity analysis was performed to evaluate the probability of side effects.

Results

The average cost incurred for inpatient treatment of infantile haemangioma was approximately $2603 for a single hospital day and increased to $2843 with the addition of an echocardiogram. The expected cost of treatment in the outpatient setting was $138, which increased to $828 after the addition of an echocardiogram.

Conclusion

Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis.

Keywords

Infantile haemangiomapropranololcost-effectiveness
Type
Original Article
Information
Cardiology in the Young , Volume 28 , Issue 10 , October 2018 , pp. 1105 - 1108
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kilcline, C, Frieden, IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25: 168–173.Google Scholar
2. Munden, A, Butschek, R, Tom, WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 2014; 170: 907–913.Google Scholar
3. Leaute-Labreze, C, Dumas de la Roque, E, Hubiche, T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649–2651.Google Scholar
4. Bennett, ML, Fleischer, AB Jr, Chamlin, SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001; 137: 1208–1213.Google Scholar
5. Boon, LM, MacDonald, DM, Mulliken, JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104: 1616–1623.Google Scholar
6. George, ME, Sharma, V, Jacobson, J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140: 963–969.Google Scholar
7. Püttgen, KB. Diagnosis and management of infantile hemangiomas. Pediatr Clin North Am 2014; 61: 383–402.Google Scholar
8. Price, CJ, Lattouf, C, Baum, B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011; 147: 1371–1376.Google Scholar
9. Phillips, RJ, Penington, AJ, Bekhor, PS, et al. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health 2012; 48: 902–906.Google Scholar
10. Xiao, Q, Li, Q, Zhang, B, et al. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int 2013; 29: 575–581.Google Scholar
11. Leaute-Labreze, C, Hoeger, P, Mazereeuw-Hautier, J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735–746.Google Scholar
12. Liu, LS, Sokoloff, D, Antaya, RJ. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas – is it indicated? Pediatr Dermatol 2013; 30: 554–560.Google Scholar
13. Hogeling, M, Adams, S, Wargon, O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259–e266.Google Scholar
14. Tang, LY, Hing, JW, Tang, JY, et al. Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol. Br J Ophthalmol 2016; 100: 902–906.Google Scholar
15. Drolet, BA, Frommelt, PC, Chamlin, SL, et al. Initiation and use of propanolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131: 128–140.Google Scholar
16. Love, JN, Sikka, N. Are 1–2 tablets dangerous? Betablocker exposure in toddlers. J Emerg Med 2004; 26: 309–314.Google Scholar
17. Cushing, SL, Boucek, RJ, Manning, SC, et al. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg 2011; 144: 78–84.Google Scholar
18. Haggstrom, AN, Drolet, BA, Baselga, E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882–887.Google Scholar
19. HCUPnet. Healthcare cost and utilization project. Agency for healthcare research and quality. Retrieved March 31, 2010, from http://www. ahrq.gov/data/hcup.Google Scholar